Proprietary AI analyst is now available

Cencora Valuation Multiples

Discover Cencora's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Fastenal, Cardinal Health, Grainger, Sumitomo and more.

Cencora Overview

About Cencora

Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.


Founded

2001

HQ

United States

Employees

51.0K

Financials (LTM)

Revenue: $333B
EBITDA: $5B

EV

$65B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cencora Financials

Cencora reported last 12-month revenue of $333B and EBITDA of $5B.

In the same LTM period, Cencora generated $12B in gross profit, $5B in EBITDA, and $3B in net income.

Revenue (LTM)


Cencora P&L

In the most recent fiscal year, Cencora reported revenue of $321B and EBITDA of $5B.

Cencora is profitable as of last fiscal year, with gross margin of 4%, EBITDA margin of 1%, and net margin of 1%.

See analyst estimates for Cencora
LTMLast FY202320242025202620272028
Revenue$333B$321B$270B$301B$325B
Gross Profit$12B$11B$9B$10B$12B
Gross Margin4%4%3%3%4%
EBITDA$5B$5B$3B$3B$4B
EBITDA Margin2%1%1%1%1%
EBIT Margin1%1%1%1%1%
Net Profit$3B$3B$2B$2B$2B
Net Margin1%1%1%1%1%
Net Debt-$3B---

Financial data powered by Morningstar, Inc.

Cencora Stock Performance

Cencora has current market cap of $55B, and enterprise value of $65B.

Market Cap Evolution


Cencora's stock price is $281.67.

Cencora share price increased by 4.6% in the last 30 days, and decreased by 6.1% in the last year.

Cencora has an EPS (earnings per share) of $16.05.

See more trading valuation data for Cencora
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$65B$55B0.0%4.6%-10.3%-6.1%$16.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cencora Valuation Multiples

Cencora trades at 0.2x EV/Revenue multiple, and 12.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Cencora

EV / Revenue (LTM)


Cencora Financial Valuation Multiples

As of June 15, 2026, Cencora has market cap of $55B and EV of $65B.

Cencora has a P/E ratio of 16.3x.

LTMLast FY202320242025202620272028
EV/Revenue0.2x0.2x0.2x0.2x0.2x
EV/EBITDA12.7x13.8x19.1x18.8x15.7x
EV/EBIT14.1x15.4x23.2x19.4x15.7x
EV/Gross Profit5.3x5.7x7.1x6.3x5.5x
P/E16.3x17.6x32.5x36.0x27.0x
EV/FCF21.2x20.3x19.5x21.3x20.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cencora Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cencora Margins & Growth Rates

Cencora grew revenue by 5% and EBITDA by 12% in the last fiscal year.

In the most recent fiscal year, Cencora reported gross margin of 4%, EBITDA margin of 1%, and net margin of 1%.

See estimated margins and future growth rates for Cencora

Cencora Margins

Last FY202420252026202720282029
Gross Margin4%3%4%4%
EBITDA Margin1%1%1%2%
EBIT Margin1%1%1%1%
Net Margin1%1%1%1%
FCF Margin1%1%1%1%

Cencora Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%11%8%5%
Gross Profit Growth12%12%15%12%
EBITDA Growth12%2%19%32%
EBIT Growth13%20%24%18%
Net Profit Growth11%(10%)33%74%
FCF Growth(3%)(9%)4%1%

Data powered by FactSet, Inc. and Morningstar, Inc.

Cencora Operational KPIs

Cencora's revenue per employee in the last FY averaged $6.3M, while opex per employee averaged $0.1M for the same period.

Cencora's Rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cencora's Rule of X is 15% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cencora
LTMLast FY202320242025202620272028
Rule of 407%7%---
Bessemer Rule of X15%15%---
Revenue per Employee-$6.3M---
Opex per Employee-$0.1M---
Opex to Revenue-2%2%2%2%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cencora Competitors

Cencora competitors include Fastenal, Cardinal Health, Grainger, Sumitomo, Rheinmetall, Ferguson, Sysco, Bunge, US Foods and Bollore.

Most Cencora public comparables operate across Wholesale Distribution.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Fastenal6.5x6.2x29.1x27.7x
Cardinal Health0.3x0.2x18.0x14.4x
Grainger3.6x3.4x21.8x20.5x
Sumitomo1.4x1.4x10.3x15.9x
Rheinmetall5.7x4.8x25.1x21.1x
Ferguson1.6x1.6x16.7x15.7x
Sysco0.6x0.6x11.9x11.7x
Bunge0.6x0.5x14.7x12.2x

This data is available for Pro users. Sign up to see all Cencora competitors and their valuation data.

Start Free Trial

Cencora VC Funding History

Before going public, Cencora raised $500M in total equity funding, across 1 round.


Cencora Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-22Secondary - public-$500M--

Acquisitions by Cencora

Cencora has acquired 10 companies to date.

Last acquisition by Cencora was on March 22nd 2026. Cencora acquired EyeSouth (retina unit) for $1B (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Cencora

EyeSouth (retina unit)
OneOncology
NextPharma Logistics
Retina Consultants of America
Description
EyeSouth (retina unit) runs a network of physician-led ophthalmology practices treating retinal conditions like macular degeneration and diabetic retinopathy. Specialists provide diagnostic imaging, surgery, and monitoring, supported by shared billing, compliance, and operations. Network practices access clinical trials and advanced therapies.
-
NextPharma Logistics is a temperature-controlled logistics provider for pharmaceuticals, handling warehousing, order fulfillment, project distribution, and returns management. Its GDP-compliant facilities in Europe store products from 2-8°C to 15-25°C with real-time tracking via SAP. Monthey-headquartered in Switzerland, it supports clinical trials and commercial supply chains for clients like Roche.
Retina Consultants of America is a management organization uniting over 200 retinal specialists across 18 states. The network provides practice management, clinical research support, and access to therapies for macular degeneration, retinal vein occlusions, and diabetic eye disease. Headquartered in New York, it facilitates physician collaboration on innovative treatments.
HQ Country-United StatesGermanyUnited States
HQ City
-
-
Bielefeld
Dallas, TX
Deal Date22 Mar 202612 Dec 202512 Oct 20256 Nov 2024
Valuation$1B$11Bundisclosed$5B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cencora acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Cencora

Cencora has invested in 2 companies to date.

Latest investment by Cencora was on September 13th 2023. Cencora invested in Sempre Health in their $20M Series C round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Cencora

Sempre Health
WhizAI
WhizAI
Description
Sempre Health is a healthcare technology company introducing dynamic pricing for prescriptions nationwide. By analyzing millions of records to predict patient behaviors, it sends personalized price offers via text to pharmacies, lowering costs, extending affordability, and improving outcomes while building datasets on price sensitivities.
-
-
HQ CountryUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
Somerset, NJ
Somerset, NJ
Deal Date13 Sep 202325 Oct 202214 Dec 2021
RoundSeries CSeries ASeries A
Raised$20M$6M$8M
InvestorsCencora; Echo Health Ventures; Industry Ventures; The Blue Venture Fund; UPMC EnterprisesCencora; Healthy Ventures; Shanda Group; Vertical Venture PartnersCencora; Shanda Group; Vertical Venture Partners
Valuationundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cencora investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cencora

When was Cencora founded?Cencora was founded in 2001.
Where is Cencora headquartered?Cencora is headquartered in United States.
How many employees does Cencora have?As of today, Cencora has over 51K employees.
Who is the CEO of Cencora?Cencora's CEO is Robert P. Mauch.
Is Cencora publicly listed?Yes, Cencora is a public company listed on NYSE.
What is the stock symbol of Cencora?Cencora trades under COR ticker.
When did Cencora go public?Cencora went public in 1995.
Who are competitors of Cencora?Cencora main competitors include Fastenal, Cardinal Health, Grainger, Sumitomo, Rheinmetall, Ferguson, Sysco, Bunge, US Foods, Bollore.
What is the current market cap of Cencora?Cencora's current market cap is $55B.
What is the current revenue of Cencora?Cencora's last 12 months revenue is $333B.
What is the current revenue growth of Cencora?Cencora revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Cencora?Current revenue multiple of Cencora is 0.2x.
What is the current EBITDA of Cencora?Cencora's last 12 months EBITDA is $5B.
What is Cencora's EBITDA margin?Cencora's last 12 months EBITDA margin is 2%.
What is the current EV/EBITDA multiple of Cencora?Current EBITDA multiple of Cencora is 12.7x.
What is the current FCF of Cencora?Cencora's last 12 months FCF is $3B.
What is Cencora's FCF margin?Cencora's last 12 months FCF margin is 1%.
What is the current EV/FCF multiple of Cencora?Current FCF multiple of Cencora is 21.2x.
How many companies Cencora has acquired to date?As of June 2026, Cencora has acquired 10 companies.
What was the largest acquisition by Cencora?$11B acquisition of OneOncology on 12th December 2025 was the largest M&A Cencora has done to date.
What companies Cencora acquired?Cencora acquired OneOncology, Alliance Healthcare, Retina Consultants of America, PharMEDium Healthcare, MWI Veterinary Supply, PharmaLex, EyeSouth (retina unit), H. D. Smith, St. Francis Group, and NextPharma Logistics.
In how many companies Cencora has invested to date?As of June 2026, Cencora has invested in 2 companies.
What was the last Cencora investment?On 13th September 2023 Cencora invested in Sempre Health, participating in a $20M Series C round, alongside Echo Health Ventures, Industry Ventures, The Blue Venture Fund, and UPMC Enterprises.
In what companies Cencora invested in?Cencora invested in Sempre Health and WhizAI.

See public comps similar to Cencora

Lists including Cencora

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial